The Family Firm’s Intellia Therapeutics NTLA Stock Holding History

The Family Firm’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15	Closed	-$336	–	628
2024 Q2	$336	Buy	+15	New	+$357	﹤0.01%	865

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

The Family Firm's NTLA Position: Q3 2024 in Review

The Family Firm sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 15 shares — an estimated $336 sold.

The Family Firm first reported a position in NTLA in Q2 2024 and held it in 1 quarter. The position peaked at $336 in Q2 2024. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

The Family Firm reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 15 Intellia Therapeutics shares in Q3 2024, an estimated $336.
The Family Firm first reported a position in Intellia Therapeutics in Q2 2024 and held it in 1 quarter.
The Family Firm's Intellia Therapeutics position peaked at $336 in Q2 2024.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.